BRISTOL-MYERS SQUIBB COMPANY Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount of $13.00 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-10-31.
Financial Statements › Notes › Debt and Equity Securities › Equity Securities without Readily Determinable Fair Value, Annual Amount
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount · last filed 2024-10-31
- BRISTOL-MYERS SQUIBB COMPANY equity securities without readily determinable fair value, downward price adjustment, annual amount for the quarter ending 2024-09-30 was $13.00M, a 116.67% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY equity securities without readily determinable fair value, downward price adjustment, annual amount for the quarter ending 2024-06-30 was $4.00M.
- BRISTOL-MYERS SQUIBB COMPANY equity securities without readily determinable fair value, downward price adjustment, annual amount for the quarter ending 2024-03-31 was $25.00M.
- BRISTOL-MYERS SQUIBB COMPANY equity securities without readily determinable fair value, downward price adjustment, annual amount for the quarter ending 2023-09-30 was $6.00M.
- BRISTOL-MYERS SQUIBB COMPANY equity securities without readily determinable fair value, downward price adjustment, annual amount for fiscal 2023 was $14.00M, a 27.27% increase from fiscal 2022.
- BRISTOL-MYERS SQUIBB COMPANY equity securities without readily determinable fair value, downward price adjustment, annual amount for fiscal 2022 was $11.00M, a 1000.00% increase from fiscal 2021.
- BRISTOL-MYERS SQUIBB COMPANY equity securities without readily determinable fair value, downward price adjustment, annual amount for fiscal 2021 was $1.00M, a 99.51% decline from fiscal 2020.
- BRISTOL-MYERS SQUIBB COMPANY equity securities without readily determinable fair value, downward price adjustment, annual amount for fiscal 2020 was $204.00M, a 655.56% increase from fiscal 2019.
| Period end | Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount 3 month | Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount 3 month as first filed | Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount 6 month | Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount 6 month as first filed | Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount 9 month | Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount 9 month as first filed | Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount 12 month |
|---|---|---|---|---|---|---|---|
| 2024-09-30 | $13.00M 10-Q · filed 2024-10-31 | $42.00M 10-Q · filed 2024-10-31 | |||||
| 2024-06-30 | $4.00M 10-Q · filed 2024-07-26 | $29.00M 10-Q · filed 2024-07-26 | |||||
| 2024-03-31 | $25.00M 10-Q · filed 2024-04-25 | ||||||
| 2023-12-31 | $14.00M 10-K · filed 2024-02-13 | ||||||
| 2023-09-30 | $6.00M 10-Q · filed 2024-10-31 | $6.00M 10-Q · filed 2024-10-31 | |||||
| 2023-06-30 | $0.00 10-Q · filed 2024-07-26 | $0.00 10-Q · filed 2024-07-26 | |||||
| 2023-03-31 | $0.00 10-Q · filed 2024-04-25 | ||||||
| 2022-12-31 | $11.00M 10-K · filed 2024-02-13 | ||||||
| 2022-09-30 | $0.00 10-Q · filed 2023-10-26 | $2.00M 10-Q · filed 2023-10-26 | |||||
| 2022-06-30 | $0.00 10-Q · filed 2023-07-27 | $2.00M 10-Q · filed 2023-07-27 | |||||
| 2022-03-31 | $2.00M 10-Q · filed 2023-04-27 | ||||||
| 2021-12-31 | $1.00M 10-K · filed 2024-02-13 | ||||||
| 2021-09-30 | $0.00 10-Q · filed 2022-10-26 | $1.00M 10-Q · filed 2022-10-26 | |||||
| 2021-06-30 | $0.00 10-Q · filed 2022-07-27 | $1.00M 10-Q · filed 2022-07-27 | |||||
| 2021-03-31 | $1.00M 10-Q · filed 2022-04-29 | ||||||
| 2020-12-31 | $204.00M 10-K · filed 2023-02-14 | ||||||
| 2020-09-30 | $2.00M 10-Q · filed 2021-10-27 | $204.00M 10-Q · filed 2021-10-27 | $203.00M 10-Q · filed 2020-11-05 | ||||
| 2020-06-30 | $14.00M 10-Q · filed 2021-07-28 | $13.00M 10-Q · filed 2020-08-06 | $202.00M 10-Q · filed 2021-07-28 | $201.00M 10-Q · filed 2020-08-06 | |||
| 2020-03-31 | $188.00M 10-Q · filed 2021-04-29 | ||||||
| 2019-12-31 | $27.00M 10-K · filed 2022-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |